Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled as the results missed investors’ expectations and reignited concerns about Novo’s rivalry with Eli Lilly.

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, though it is exploring oral semaglutide for obesity.

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes that its position as a market leader for insulin products in the country could give it an edge.